Application of genetically engineered biopharmaceutical products in children with various JIA forms in the Karaganda region

Abstract

The article presents the experience of using biopharmaceutical products for the treatment of children with juvenile idiopathic arthritis in the cardio-rheumatological department of the PSE “Children’s Hospital of Karaganda” for the period from January 1, 2013, to December 31, 2017. The study included 46 patients with JIA who were on genetically engineered biological therapy (girls 28-60.8%, boys 18-39.1%). Among all patients, 12 (26.1%) suffered from the oligoarticular variant of juvenile idiopathic arthritis with (JIA), 15 (32.6%) – from polyarticular seronegative variant (JIA), 14 (30.4%) – from systemic form (JIA), and 5 (10.9%) from other variants. Adalimumab was used in 24 patients (50.2%). Tocilizumab in 17 (30%) ones, 14 of which had a systemic variant of JIA. Infliximab was applied for 5 patients (10.8%).